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Abstract
Background—Children with sickle cell disease (SCD) and moyamoya may benefit from indirect 
cerebral revascularization surgery in addition to chronic blood transfusion therapy for infarct 
prevention. We sought to compare overt and silent infarct recurrence rates in children with SCD 
undergoing revascularization.
Methods—This was a retrospective cohort study of all children with SCD and moyamoya treated 
at two children’s hospitals. Clinical events and imaging studies were reviewed.
Results—Twenty-seven children with SCD and confirmed moyamoya receiving chronic 
transfusion therapy were identified, of whom 12 underwent indirect cerebral revascularization. 
Two subjects had post-operative transient ischemic attacks and another had a subarachnoid blood 
collection, none of which caused permanent consequences. Two subjects had surgical wound 
infections. Among these 12 children, the rate of overt and silent infarct recurrence decreased from 
13.4 infarcts/100 patient-years before revascularization to 0 infarcts/100 patient-years after 
revascularization (p=0.0057); the post-revascularization infarct recurrence rate was also 
significantly lower than the overall infarct recurrence of 8.87 infarcts/100 patient-years in 15 
children without cerebral revascularization (p=0.025).
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Conclusion—The rate of overt and silent infarct recurrence was significantly lower following 
indirect cerebral revascularization. A prospective study of cerebral revascularization in children 
with SCD is needed.
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Introduction
Children with sickle cell disease (SCD) have approximately 250 times greater risk for 
strokes than the general pediatric population.[1,2] The historical prevalence of overt stroke 
was approximately 11% in those with hemoglobin (Hb) SS disease by age 20 years.[2] 
Chronic blood transfusion therapy is the standard therapy for primary and secondary 
prevention of stroke in children with SCD, reducing the risk of first stroke by 90%[3] and of 
recurrent stroke from approximately 70% to 20%.[4,5] Chronic transfusion therapy does not 
eliminate stroke risk, however. Recurrent stroke rates despite chronic transfusion therapy 
range from 2.0 overt plus silent strokes/100 patient-years in children with a history of silent 
strokes[6] to 8.1 overt plus silent strokes/100 patient-years in those with prior overt strokes.
[7]
Moyamoya is a continuum of progressive large vessel cerebral vasculopathy, characterized 
by stenosis and occlusion of arteries of the circle of Willis with eventual collateral vessel 
formation. It occurs spontaneously or in the context of systemic disorders, causing recurrent 
cerebral infarctions, transient ischemic attacks (TIAs), and cerebral hemorrhages. 
Moyamoya syndrome and progressive cerebral vasculopathy are prevalent in children with 
SCD and overt strokes despite chronic transfusion therapy and are a significant cause of 
recurrent silent and overt strokes. In a retrospective cohort study, the presence of moyamoya 
collateral vessels conferred a relative risk of recurrent overt stroke of 2.4,[8] while children 
with progressive cerebral vasculopathy, including progressive arterial stenosis or moyamoya 
collateral vessels, had a relative risk of recurrent overt or silent infarction of 12.7 in a 
prospective cohort study.[7]
Based on experience in children with non-SCD moyamoya, many centers perform cerebral 
revascularization in children with SCD and moyamoya, typically an indirect 
revascularization approach.[9,10] Indirect revascularization, including the commonly-used 
pial synangiosis technique, relies on ingrowth of new collateral vessels into the brain tissue 
and typically results in symptomatic improvement within several weeks to months post-
operatively. In pial synangiosis, an intact segment of the superficial temporal artery is 
mobilized, and a bone flap is created. The dura and arachnoid are opened and the intact 
superficial temporal artery segment is sutured to the pial surface, without cutting or 
clamping the artery at either end. Finally, grooves are cut in the bone flap to accommodate 
the arterial segment, and the flap is replaced.[10–12] While several case series suggest that 
pial synangiosis is safe in children with SCD and moyamoya syndrome and reduces their 
risk of recurrent overt strokes,[9] its effect on silent cerebral infarctions (SCIs) has not been 
determined. We undertook a two-center retrospective cohort study to determine the 
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neurologic outcomes of children with SCD and moyamoya syndrome on chronic transfusion 
therapy who underwent cerebral revascularization surgery compared with those on chronic 
transfusion therapy who did not undergo cerebral revascularization. We hypothesized that 
cerebral revascularization surgery reduces silent and overt infarct recurrence in children with 
SCD and moyamoya syndrome when compared to children who do not undergo cerebral 
revascularization surgery.
Methods
A retrospective cohort study was performed at two academic centers, Riley Hospital for 
Children at Indiana University Health and St. Louis Children’s Hospital/Washington 
University School of Medicine, of patients with SCD and severe cerebral vasculopathy. At 
both sites, patients with overt strokes or cerebral vasculopathy undergo surveillance brain 
magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA) studies 
approximately annually to monitor for development of new infarcts or progressive cerebral 
vasculopathy. Cerebral revascularization, typically via pial synangiosis,[12] is offered to all 
patients with severe cerebral arterial stenosis or occlusion (as determined by digital 
subtraction angiography or computed tomography angiography) with or without moyamoya 
collateral vessel formation and regardless of cerebral infarcts or TIAs. Both centers follow 
the perioperative guidelines published by Smith et al,[13] including goal perioperative Hb 
concentration of 10 to 11 g/dL and Hb S <30%. Aspirin is prescribed to all children prior to 
revascularization surgery at both sites and is continued through the perioperative period. 
Following revascularization surgery, all children continue aspirin indefinitely. Aspirin is also 
prescribed to some children with severe vasculopathy/moyamoya who do not undergo 
cerebral revascularization surgery at their physician’s discretion. Additionally, all patients 
continue chronic blood transfusion therapy postoperatively, unless they receive a 
hematopoietic stem cell transplant (HSCT).
Patients at both medical centers who received chronic transfusion therapy between 2000 and 
2014 due to abnormal transcranial Doppler ultrasonography (TCD) or overt or silent stroke 
were reviewed. For inclusion, we required that severe cerebral vasculopathy be described in 
the clinical reports of two or more MRI studies or confirmed on conventional angiogram or 
computed tomography (CT) angiogram, since turbulent blood flow may cause the artifactual 
appearance of arterial stenosis on time-of-flight MRA.[14] Exclusion criteria were 
incomplete medical records, lack of confirmation of severe cerebral vasculopathy on two 
imaging studies, and lack of chronic blood transfusion therapy. Institutional Review Board 
approval with waiver of informed consent was obtained at both sites.
Two investigators (E.M.H. and M.L.H.) reviewed all available medical records at Riley 
Hospital for Children at Indiana University Health and St. Louis Children’s Hospital for the 
following data: patient demographics; dates and symptoms of all strokes; date of and reason 
for initiation of chronic transfusion therapy; Hb S percentage goal for transfusion therapy; 
treatment with aspirin; dates and results of all brain imaging studies; dates, laterality, and 
outcomes of cerebral revascularization procedures; duration of follow-up; and date of 
hematopoietic stem cell transplant. New infarcts and cerebral vasculopathy progression were 
determined by reviewing clinically reported results of brain MRI/MRAs. Overt strokes were 
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defined as new neurological symptoms either lasting greater than 24 hours or having an area 
of diffusion restriction or a T2 or fluid-attenuated inversion recovery (FLAIR) hyperintensity 
on MRI that was consistent with the neurological findings; SCIs were defined as T2 or 
FLAIR hyperintensities on brain MRI that did not correlate with any reported neurological 
symptoms. Severe cerebral vasculopathy was defined as occlusion or near-occlusion of the 
internal carotid or middle cerebral arteries on clinically reported MRAs, CT angiograms, or 
conventional angiograms, with or without the presence of moyamoya collateral vessels. 
TIAs were defined as acute neurological symptoms lasting less than 24 hours, typically 
hemiparesis or hemisensory loss, that did not have a correlating new area of diffusion 
restriction or T2 or FLAIR hyperintensity on MRI. Study data were collected and managed 
using REDCap electronic data capture tools hosted at Washington University School of 
Medicine.[15]
Statistical Methods
Categorical variables were compared using Fisher’s exact test, and continuous variables 
were analyzed using non-parametric tests. Incidence rates were compared with Poisson 
distribution. The level of significance was specified as <0.05. The Bejamini-Hochberg 
procedure was used, with a false discovery rate of 0.05.[16] SPSS version 21 (IBM, 
Armonk, NY) was used for statistical analysis.
Results
Forty children were identified with SCD and potential severe cerebral vasculopathy, of 
whom 13 were excluded (lack of imaging confirmation in eight, lack of chronic transfusion 
therapy following diagnosis of stroke in three, and inadequate medical records in two). 
Despite incomplete clinical and imaging records, the excluded children were severely 
affected, with 6 of 13 having recurrent silent or overt strokes or TIAs while receiving 
chronic transfusion therapy or HSCT. Twenty-seven children met all inclusion criteria; 15 
(56%) were male. One subject had Hb S-β+ thalassemia and the other 26 had Hb SS or S-β0 
thalassemia. Figure 1 shows the children evaluated for inclusion and the number of MRI/
MRAs reviewed.
Patient characteristics
Median age at initiation of chronic transfusion therapy was 6.83 years (interquartile range 
[IQR] 5.4–10.28). The indication for chronic transfusion therapy initiation was abnormal 
TCD in 3 (11%), overt stroke in 19 (70%), and SCI in 5 (18%) (Table I). Twenty-six of 27 
patients included for analysis had cerebral infarcts documented at initiation of chronic 
transfusion therapy: 7 had overt stroke, 6 had silent stroke, and 13 had both overt and silent 
strokes. One child who started transfusion therapy due to an abnormal TCD and three 
children with overt strokes had their first MRI or MRA performed several months to years 
later; therefore, these four subjects’ silent stroke burden and presence or severity of 
vasculopathy was unknown at transfusion therapy initiation. Chronic transfusion goals were 
to maintain Hb S <30% in all subjects for 2 years after starting transfusion therapy; 
subsequently the goal remained <30% in 21(78%) and was liberalized to <50% in 6 (22%). 
Subjects had a total of 263.1 patient-years of follow-up after initiation of transfusion therapy, 
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median 9.68 years (IQR 5.33–13.65). A total of 203 MRI/MRA reports were reviewed. Two 
subjects died during the follow-up period: a 20-year-old female who did not undergo 
cerebral revascularization surgery died of complications of a matched unrelated donor 
HSCT, and a 21-year-old male died of acute multisystem organ failure without further 
details available, approximately two years following cerebral revascularization.
Fourteen of 27 children (52%) had new or enlarging silent infarcts identified on MRI or 
recurrent overt strokes during the follow-up period (range 0–3 new infarcts per patient), 
yielding an overall silent plus overt infarct recurrence of 7.98 events/100 patient-years.
Cerebral vasculopathy was present at initiation of chronic transfusion therapy in 20 (74%) 
and was identified after initiation of chronic transfusion therapy in 3 (11%). Presence of 
cerebral vasculopathy at the time of transfusion therapy initiation was unknown in four 
subjects (15%), two of whom had initial MRIs performed at a referring institution (thus 
imaging studies were unavailable for review) and two of whom did not undergo MRA at 
initiation of chronic transfusion therapy. During the follow-up period, 23 (85%) of the 
children had progression of cerebral vasculopathy identified on clinical MRAs. Progression 
of vasculopathy was associated with new overt and silent infarcts (odds ratio 2.6, 95% CI 
1.6, 4.3; Fisher’s exact test p = 0.041).
Comparison of revascularization and no revascularization groups
Indirect cerebral revascularization surgery was performed in 12 of 27 children, at a median 
4.03 years (IQR 1.87–7.04) following initiation of chronic transfusion therapy. The 
indications for revascularization surgery, as documented by subjects’ treating physicians, 
were TIA, recurrent silent or overt stroke, progressive vasculopathy, educational problems/
school failure, and/or headaches; 11 children had more than one of these signs of progressive 
cerebrovascular disease despite chronic transfusion therapy. (Table I). Compared with 
children who did not undergo cerebral revascularization, those in the revascularization group 
were younger at chronic transfusion therapy initiation (median 5.5 years, IQR 3.5–9.1, vs 
median 7.7 years, IQR 6.3–10.7, p=0.037) and were more likely to have TIAs (8/12 
children, 66.7%, vs 3/15 children, 20%, p=0.02). There was no difference in sex, duration of 
follow-up after beginning transfusion therapy, presence of overt or silent strokes or cerebral 
vasculopathy at transfusion therapy initiation, headaches, or school failure between the 
groups (Table I). All 12 children in the revascularization group were prescribed aspirin, 
along with 3/15 (20%) of children who did not have revascularization (p<0.001).
Cerebral revascularization surgery and immediate postoperative outcomes
Eleven children underwent pial synangiosis (4 unilateral, 7 bilateral) and one child 
underwent bilateral burr hole placement with dural opening, for a total of 20 hemispheres 
treated. Six subjects with bilateral vasculopathy had staged pial synangiosis, with 
approximately one month separating the two hemispheres’ surgeries, while one subject had 
pial synangiosis performed on both hemispheres on the same day. Two children experienced 
post-operative TIAs localizing to the operated cerebral hemisphere, both without new infarct 
lesions on MRI. No children had strokes in the immediate post-surgical period. One subject 
Hall et al. Page 5
Pediatr Blood Cancer. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
developed a small subarachnoid blood collection post-operatively that caused fevers and 
headache; symptoms resolved with a short course of corticosteroids.
Three children incurred non-neurologic surgical complications. Two children developed a 
post-operative wound infection, both of which resolved with antibiotics, and one child had 
false tracking of a Foley catheter prior to surgery. None of the surgical complications 
resulted in permanent consequence to the affected patients.
Comparison of infarct recurrence between groups
Prior to cerebral revascularization, silent plus overt infarct recurrence in the 
revascularization group was 13.4 events/100 patient-years during 59.63 patient-years of 
follow-up (95% CI 5.79, 26.4), not significantly different from the silent plus overt infarct 
recurrence rate of 8.87 events/100 patient-years in the non-revascularization group during 
146.45 patient-years of follow-up (95% CI 4.73, 15.2) (p=0.4). Following cerebral 
revascularization, the infarct recurrence rate in the revascularization group was 0 events/100 
patient-years during 57.0 patient-years of follow-up. This was significantly lower than this 
group’s pre-revascularization infarct recurrence rate (p=0.0057), and furthermore was 
significantly lower than the overall infarct recurrence rate in the non-revascularization group 
(p=0.025). Thus while the infarct recurrence rate was similar between groups at baseline, the 
children who underwent revascularization had a significant reduction in infarct recurrence 
post-revascularization compared with their own baseline and with the non-revascularization 
group (Figure 2).
Three of the eight children with history of TIAs had no additional TIAs following cerebral 
revascularization surgery; the remaining five children reported a decreased frequency and 
severity of TIA events. None of the 4 patients without pre-revascularization TIAs developed 
TIAs post-operatively.
Aside from the subarachnoid blood collection in a post-revascularization patient noted 
above, there were no other intracranial or other hemorrhages in 15 children receiving aspirin. 
One subject with moyamoya collaterals who neither took aspirin nor underwent cerebral 
revascularization therapy had a spontaneous intraventricular hemorrhage, causing acute 
hydrocephalus and a new SCI; he had prior overt strokes and progressive moyamoya despite 
chronic transfusion therapy.
HSCT and cerebral vasculopathy
Five children, all female, received HSCT during the study period: one matched sibling 
donor, three matched unrelated donor, and one haploidentical transplant. Two teens, neither 
of whom underwent cerebral revascularization, had new infarcts following HSCT: a 15-year-
old had an overt stroke 2 months after HSCT and posterior reversible encephalopathy 
syndrome 8 months after HSCT resulting in hemiparesis and chronic infarcts on MRI, and a 
19-year-old had stable infarcts on MRI 7 months after HSCT but progression of SCIs on 
MRI 15 months after HSCT. This latter subject subsequently died of multisystem organ 
failure 18 months after HSCT. A 10-year-old underwent matched unrelated donor HSCT 18 
months after bilateral cerebral revascularization without any post-HSCT neurological 
complications. The recipients of matched sibling donor (age 7 years) and haploidentical (age 
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21 years) HSCT had no neurological complications following transplant; neither of them 
have undergone cerebral revascularization.
Figure 3 depicts the longitudinal course of each patient from transfusion therapy initiation to 
last follow-up, with silent and overt strokes, TIAs, revascularization surgery, and HSCT 
denoted.
Discussion
In this cohort study, both overt and silent stroke recurrence declined after cerebral 
revascularization surgery, providing further evidence that indirect cerebral revascularization 
is beneficial in children with SCD and moyamoya. Our report adds 12 cases of cerebral 
revascularization surgery in children with SCD, increasing the published total to 74 children, 
encompassing 118 cerebral hemispheres.[9,13,17–20] In all of these series, overt stroke 
recurrence is decreased following revascularization surgery. In addition, we provide the first 
indication that cerebral revascularization may reduce SCI recurrences in children receiving 
transfusion therapy.
This cohort of children with SCD and vasculopathy/moyamoya had an overall infarct 
recurrence rate on transfusion therapy of 7.98 infarcts/100 patient-years, comparable with a 
previously published cohort of children receiving chronic transfusion therapy for secondary 
stroke prevention.[7] The children in the revascularization surgery group had several features 
that may indicate more severe cerebrovascular disease, including younger age at initiation of 
chronic transfusion therapy and occurrence of TIAs, but their pre-revascularization infarct 
recurrence rate was similar to the children in the no revascularization group. The 
significantly lower infarct recurrence rate following indirect revascularization, despite the 
subjects’ more severe preoperative features, suggests that children with SCD and severe 
cerebral vasculopathy/moyamoya but without TIAs or recurrent infarcts may derive similar 
benefit. Further, our data suggest that children may benefit more from this procedure before 
they have had multiple cerebral infarcts, since each infarct carries a risk of physical and 
cognitive morbidity.
While not clinically obvious, SCIs cause significant intellectual impairment among children 
with SCD. In the Silent Infarct Transfusion study, the presence of SCIs was associated with 
a 5-point decrease in intelligence quotient (IQ).[21] The severity of intellectual impairment 
worsens with increasing volume of cerebral infarction,[22] and children with overt strokes 
have even poorer cognition than those with SCIs alone.[23,24] Cognition in children with 
moyamoya due to SCD is more impaired than in subjects with non-SCD moyamoya, with 
lower baseline IQ and a further decline in IQ after a median follow-up of 3 years.[25] By 
extension, our data showing prevention of both SCIs and overt strokes following indirect 
revascularization suggest that revascularization may limit cognitive deterioration in children 
with SCD and moyamoya. Not surprisingly, more than half of our subjects had significant 
school difficulties or grade failure. However, due to the study’s retrospective design, we 
could not compare cognitive outcomes in children in the revascularization and no 
revascularization groups.
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The impact of TIAs on recurrent stroke risk and quality of life has not been quantified in 
children with SCD and moyamoya. The Cooperative Study of Sickle Cell Disease identified 
TIA as the strongest clinical risk factor for first stroke, with a relative risk of 56 for future 
first stroke.[2] In our study, subjects with TIAs were more likely to undergo cerebral 
revascularization surgery, potentially reflecting clinicians’ and parents’ concern that TIAs 
portend a more serious clinical event. All eight of the children in our study who had TIAs 
and underwent cerebral revascularization surgery had reduction or elimination of TIAs post-
operatively, suggesting improvement in brain oxygen delivery; however, the continued TIAs 
in some of the children strongly suggest that they remain at risk of cerebral infarction.
This study is limited chiefly by its small sample size and retrospective design. Infarct 
recurrence risk may change over time, even in children with moyamoya. In this cohort, 
children were offered revascularization surgery at different timepoints after diagnosis of 
moyamoya, which may have limited our ability to discern differences in infarct recurrence 
rate between subjects who did and did not undergo revascularization. Our data set was 
limited by lack of Hb S concentrations in subjects in both groups. While common practice is 
to maintain Hb S concentrations below 30% on transfusion therapy, the optimal transfusion 
target has not been defined in prospective studies.[26] Furthermore, multiple cohort studies 
have identified progressive cerebral vasculopathy/moyamoya and infarctions in patients with 
SCD despite Hb S concentrations maintained below 30%[7,27,28] or even following 
successful HSCT.[29] These reports, plus the fact that moyamoya occurs in many patient 
populations without SCD, suggest that correction of Hb S is inadequate to prevent cerebral 
vasculopathy/moyamoya progression once this pathological cascade is initiated.[30] Finally, 
because aspirin treatment was significantly more common in children who underwent 
revascularization surgery, it is possible that the reduction in stroke recurrence rate is in part 
due to the effect of aspirin. However, this seems unlikely for several reasons. First, aspirin 
alone is not the standard treatment for children with idiopathic moyamoya or moyamoya due 
to other syndromes;[11] second, some centers have reported similar reductions in overt 
stroke recurrences following cerebral revascularization in SCD patients not prescribed 
aspirin,[9,20] suggesting that cerebral revascularization, and not aspirin, is the cause of 
improvement. Even with these limitations, our results corroborate prior publications 
indicating a significant reduction in both overt and silent stroke recurrence rate following 
revascularization.
There is no standard approach to management of progressive cerebral vasculopathy in 
children with SCD. HSCT, the only curative therapy for SCD, has been recommended as a 
treatment for cerebral vasculopathy by some[31] but is not available for all patients due to 
lack of matched sibling donors or adequately matched alternative donors. While successful 
HSCT provides long-term protection against overt strokes in most recipients, vasculopathy 
progression following HSCT has been reported in several cohorts,[29,32] suggesting that, 
once initiated, vasculopathy may progress independently of the presence of sickled red 
blood cells. Our data suggest that children may remain at risk of recurrent or progressive 
infarcts following HSCT if they have severe vasculopathy/moyamoya prior to HSCT, with 
two subjects in our study having new overt or silent infarcts post-HSCT. Whether pre-HSCT 
cerebral revascularization provides additional protection against neurological injury in 
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children undergoing HSCT is unknown and should be investigated in upcoming clinical 
studies.
Given the relative rarity of moyamoya in children with SCD, therapy options have not been 
studied prospectively. Cerebral revascularization is recommended for children with SCD and 
moyamoya at many centers based on its demonstrated benefit in children with idiopathic 
moyamoya or moyamoya due to other syndromes.[33] Pial synangiosis has been reported 
most frequently in children with SCD, but other surgical approaches include burr hole 
placement with dural opening, an indirect revascularization approach relying on ingrowth of 
new blood vessels, and direct anastomosis between the superficial temporal artery and 
middle cerebral artery, which immediately restores blood flow but is more technically 
difficult in children.[34] The small numbers of subjects in each of the published SCD 
cohorts indicate a need for prospective multicenter studies incorporating measures of 
cerebral function such as cognition and oxygen metabolism[35] as well as structural 
MRI/MRA and patient-reported outcomes. Such studies will improve understanding of the 
impact of treatments including cerebral revascularization, chronic transfusion therapy, and 
HSCT on TIAs, cerebral infarctions, and quality of life.
In conclusion, while multiple studies have shown that children with SCD and moyamoya 
have a significantly lower rate of overt stroke recurrence following cerebral revascularization 
surgery, this is the first to specifically describe protection from SCI recurrence. Prospective 
studies are needed to compare outcomes of cerebral revascularization with other treatment 
options for children with SCD and moyamoya.
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Figure 1. 
Subjects Evaluated for Analysis
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Figure 2. 
Comparison of Silent plus Overt Infarct Recurrence Incidence while Receiving Chronic 
Transfusion Therapy. The 12 subjects who underwent cerebral revascularization surgery had 
a significant reduction in incidence of infarct recurrence compared to their own pre-
revascularization baseline (*p=0.0057), and compared to the infarct recurrence incidence in 
the 15 subjects who did not undergo revascularization (**p=0.025).
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Figure 3. 
Time Course of Infarct Recurrence, TIAs, and Revascularization Surgery Following 
Initiation of Chronic Transfusion Therapy for Stroke Prevention. Each horizontal line 
represents a single patient, with neurological events and treatments denoted. Patients 1–15 
did not have revascularization surgery, while patients 16–27 had revascularization surgery. 
Patients 16, 17, 18, and 24 had unilateral revascularization, while the rest of the patients in 
the revascularization group had bilateral revascularization surgery.
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Table I
Neuroimaging, Clinical Symptoms, and Treatments Prescribed for Children with Sickle Cell Disease and 
Severe Cerebral Vasculopathy
Revascularization surgery (N=12) No revascularization 
surgery (N=15)
P value
Sex (% male) 67 47 0.4
Median age at transfusion therapy initiation (y) 5.6 7.7 0.037*
Median time followed after initiation of transfusion 
therapy (y)
9.5 9.7 0.9
Present at transfusion therapy initiation
 Cerebral infarction 11 (91.7%) 15 (100%) 0.4
  Overt 10 (83.3%) 10 (66.7%) 0.4
  Silent 8 (66.7%) 12 (80%) 0.7
 Abnormal TCD 3 (25%) 1 (6.7%) 0.3
 Vasculopathy 9 (75%) 10 (66.7%) 0.7
Neurological symptoms or signs after transfusion 
therapy initiation
 New infarct 6 (50%) 8 (53.3%) 1
  New overt 3 (25%) 7 (46.7%) 0.4
  New silent 4 (33.3%) 3 (20%) 0.7
 TIA 8 (66.7%) 3 (20%) 0.02**
 Vasculopathy progression 10 (83.3%) 13 (86.7%) 1
 Headaches 5 (41.7%) 5 (33.3%) 0.7
 Educational problems or grade failure 8 (66.7%) 9 (60%) 1
Other treatments
 Aspirin 12 (100%) 3 (20%) <0.001**
 HSCT 1 (8.3%) 4 (26.7%) 0.3
TCD = transcranial Doppler ultrasound, TIA = transient ischemic attack, HSCT = hematopoietic stem cell transplant.
*
Independent-samples Mann-Whitney U test,
**
Fisher’s exact test.
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